Table 2.

Proportion achieving a target urate level by treatment type

Urate-lowering therapy	% achieving target level (<5 mg/dL unless stated)
APL monotherapy (various studies)	30%–70%a,4
High-dose APL (up to 600 mg)	78%,7 69%6
Feboxustat versus APLa,9	APL 300 mg 40% FBX 40 mg 49% FBX 80 mg 70%
APL plus benzbromarone v APLa,9	APL 60% Combination 74%
APL plus probenecid	65%10
APL ± LESU
APL alone	28%12
APL plus LESU 200 mg	63%a,11, 54%12
APL plus LESU 400 mg	78%a,11, 59%12
Feboxustat ± LESU
Feboxustat monotherapy	67% 80 mga,13 56% 40 mga,13 47% 80 mg14
Feboxustat plus LESU 200 mg	56%14
Feboxustat plus LESU 400 mg	100%a,13, 76%14

Note:

^a<6 mg/dL.

Abbreviations: APL, allopurinol; LESU, lesinurad; FBX, feboxustat.